Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

The cause of most concern are seed oils - a type of vegetable oil derived from plant seeds but the cause of most concern are ...

American Academy of Dermatology (AAD) meeting, Steven Daveluy, M.D., associate professor and program director of dermatology ...

Here's the latest news and everything you need to know about the first major wave of NFL player movement this spring.